

Keyword Index

A

A3A	A003
adaptable cancer cell state	A010
adaptive therapy	PR005, A026, B012
anaplastic large cell lymphoma	B037
antibody-dye-conjugates	A028
anti-cancer evolution	B002
apoptosis	A014
aprocitentan	A014
artificial intelligence	A029
ASCL1	A006

B

bHLH transcription factors	A006
biochemical recurrence	B036
biomarkers	B034
bone	PR002, A008
bone metastasis	A019
breast cancer	A014, B024

C

cancer associated fibroblast	A018
cancer care	A029
cancer cell	B010
cancer cell quiescence	A010
cancer diagnosis	A021
cancer epidemiology	A011
cancer evolution	A005, B022, B035
cancer evolution modeling	B030
cancer model	A036
cancer surge	B028
case report	A034
castration-resistant prostate cancer	B013
cell mechanics	A012
cell proliferation	B010

cell-free DNA	B013
cell-state transitions	B035
cellular barcoding	A001
chemotherapy resistance	B016
CIN	A003
clade	B005
clinical data integration	A020, A021
clinical trials	A027
clonal evolution	B008, B011
clonal selection	B018
colorectal cancer	PR004, A018, A032, B021
comparative genomics	B029, B040
computational	B032
computational analysis	B029
computational modeling	B035
computational pathology	A015
computational pipelines	B040
confidence score analysis	B031
convergence	B003
CRC	A031
D	
DCIS	A016
DCIS progression to breast cancer	A016
DCIS recurrence	A016
decellularized extracellular matrix hydrogel	A036
diffuse midline glioma	A025
digital pathology	A016, B027
discontinuation	A027
dormancy	A017
drug repurposing	A014
drug response	A033, B010
drug response prediction	B038
E	
ecological dynamics	A016
endoscopic diagnostics	A032
endothelin receptors	A014

**CANCER EVOLUTION: THE DYNAMICS
OF PROGRESSION AND PERSISTANCE**

IN ASSOCIATION WITH THE AACR Cancer Evolution Working Group (CEWG)
December 4-6, 2025 | Albuquerque, NM

ensemble learning	A020
environmental	PR002, A008
epidemiology	B001
epigenetic remodeling	B018
epigenetics	B003
esophageal cancer	A036
evolution	B001, B017
evolution of therapeutic resistance	B014
evolutionary therapy	B037
evolutionary tradeoff	B012
explainable AI	A032
G	
G3i	B020
generative AI	A030
genomic associations with epigenomic state	B013
glioblastoma	A006
glioma	B032
glioma stem cells	A006
glucose	A012, B020
GLUT3	B020
gut-liver	A031
H	
hallmarks of cancer	B005
heavy metals	A011
HER2 heterogeneity	B011
heterogeneity	B007
histopathology	A020, A021
I	
immune escape	B022
immunoediting	B042
immuno-engineering	A028
in vivo functional genomics	IA006
intrinsic resistance	A010
in-vivo imaging	B005
I-TASSER	B031

**CANCER EVOLUTION: THE DYNAMICS
OF PROGRESSION AND PERSISTANCE**

IN ASSOCIATION WITH THE AACR Cancer Evolution Working Group (CEWG)
December 4-6, 2025 | Albuquerque, NM

K	
kinase inhibition	B010
KRAS	A002, B031
Kudo pit pattern	A032
L	
L1CAM	A009
Li-Fraumeni Syndrome	B004, B033
Linear chain trick (LCT) model	B026
loss of heterozygosity	B004
lung adenocarcinoma	A002
lung adenocarcinoma metastasis	A009
lung cancer	A021
M	
macrophage	B024
magic bullet	A028
masked modelling	A021
MASLD	A031
mathematical biomarker	PR005, A026
mathematical oncology	B037
matrisome	B023
MDA-MB-231	B020
MDM2-MDMX protein	B028
melanoma	A020, A027
metabolic rewiring	B025
metabolism	PR003, A013
metastasis	PR002, A007, A008
methylation	B034
microenvironment	A016, A017
molecular epidemiology	A011
multi-agent AI	A032
multimodal AI	A032
multimodal analysis	A020
multi-omics profiling	B018
multiple-instance learning (MIL)	A020
mutation interpretation	A030
mutation rate	B039

**CANCER EVOLUTION: THE DYNAMICS
OF PROGRESSION AND PERSISTANCE**

IN ASSOCIATION WITH THE AACR Cancer Evolution Working Group (CEWG)
December 4-6, 2025 | Albuquerque, NM

mutation timing	B022
mutations	B032
N	
natural language processing (NLP)	A032
natural selection	B001
neoantigens	B042
neural network	A033
noncanonical antigen	A025
non-genetic states	A001
non-traditional model systems	B002
O	
OLIG2	A006
oncogenesis	A001
ovarian cancer	B016
P	
p53	B033
pancreas	PR003, A013
pancreatic cancer	A014, B023
pancreatic ductal adenocarcinoma	B027
pan-mammalian tumor compendium	B040
PanNET grade transformation	B025
parallel evolution	A007
patient-derived fibroblasts	B004
PDAC	A003
pediatric brain cancer	B008
peritoneal metastasis	A018
personalized treatment	PR005, A026
phylogenetic distance metrics	B008
phylogenetics	B034
phylogeny	A007
planar cell polarity	A009
plasticity	B019
polyaneuploid/polyploid giant cancer cells (paccs/pgccs)	B026
polyp detection	A032
precancer	PR003, A013

**CANCER EVOLUTION: THE DYNAMICS
OF PROGRESSION AND PERSISTANCE**

IN ASSOCIATION WITH THE AACR Cancer Evolution Working Group (CEWG)
December 4-6, 2025 | Albuquerque, NM

pre-cancer	B005
precision oncology	A033
precision oncology	A023, A024, B038
precision oncology AI	B030
premalignant	A002
primary cardiac leiomyosarcoma	A034
prostate cancer	A019, B003, B036
protein language models	A030

R

reasoning models	A032
remote communities	A029
resistance	B012, B017, B019
risk stratification	A016
RNA-seq	B029

S

selection	B039
signal transduction	B010
single cell sequencing	B025
single cell transcriptomics	B033
single-cell	A019
single-cell sequencing	A005
single-cell-phylogeny	B041
skin cancer	A020, B005
smarcb1	B017
soft tissue sarcoma	A034
solar elastosis	A020
somatic mosaicism	B005
spatial analysis	PR004, B021
spatial ecology and landscape metrics	A015
spatial interactions	A016
spatial transcriptomics	B038
stochastic tumor evolution	IA006
stress	B007
structural variations	B016
subclonal-fitness	B041

T

CANCER EVOLUTION: THE DYNAMICS OF PROGRESSION AND PERSISTANCE

T cell receptor	A025
targeted anticancer design	B028
targeted therapy	B010
T-DXd	B011
TEAD	B020
temporal proteomics	B023
therapy resistance mechanisms	IA006
TNBC	A012, B020
transcriptomics	B036
transdifferentiation	B019
transmissible cancer	B002
treatment resistance	A005
treatment response	B007
tumor evolution	B039
tumor genome	A023
tumor heterogeneity dynamics	B030
tumor microenvironment	A015, A021, B024, B027
tumor sequencing	B042
tumor vulnerability	A024
tumour-immune dynamics	PR004, B021
U	
ultraviolet	B005
V	
VASP	B020
virus	A017
W	
whole genome doubling (WGD) and karyotype evolution	B026
whole slide images (WSIs)	A020
whole-genome-doubling	B041
Y	
YAP	B020

**CANCER EVOLUTION: THE DYNAMICS
OF PROGRESSION AND PERSISTANCE**

IN ASSOCIATION WITH THE AACR Cancer Evolution Working Group (CEWG)
December 4-6, 2025 | Albuquerque, NM